Brief: Interim Results From Ongoing Clinical Study Confirm Eb613 Optimized Profile For Osteoporosis Treatment And Potential For Entera’S Next Generation Oral Peptide Platform
29/11/2023 15:59
Entera Bio Ltd 5DT.F :
* INTERIM RESULTS FROM ONGOING CLINICAL STUDY CONFIRM EB613
OPTIMIZED PROFILE FOR OSTEOPOROSIS TREATMENT AND POTENTIAL FOR
ENTERA’S NEXT GENERATION ORAL PEPTIDE PLATFORM
* ENTERA BIO LTD - EB613 CONTINUES TO DISPLAY AN OPTIMAL
PROFILE
AS FIRST-IN-CLASS ORAL PTH(1-34) PEPTIDE FOR OSTEOPOROSIS
Source text for Eikon: ID:nGNX5dJdHQ
Further company coverage: 5DT.F
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement